Q2 Drug Approvals and Biosimilar Changes Impacting Your Pharmacy Strategy
The second quarter of 2025 has brought a steady flow of movement in the FDA pipeline, biosimilars gaining even more […]
Articles
7 Key Things You Need to Know About Tariffs and Pharmaceuticals
There’s been renewed attention on tariffs following the April 2, 2025 executive order introducing reciprocal trade measures. While pharmaceuticals are
How the 2025 American Diabetes Association Guidelines Will Impact Your Pharmacy Benefit Strategy
By Jason Peterson, RPh; Beckie Fenrick, PharmD, MBA; and Emily Crisano, PharmD, RPh The American Diabetes Association (ADA) recently released
5 Ways to Win RFP Season (Before It Even Starts)
Even the most seasoned brokers can overlook small details that make a big impact during RFP season. With timelines tightening
Weight Management Benefits: A Strategic Guide for Brokers and their Plan Sponsors
By Beckie Fenrick, PharmD, MBA; Emily Crisano, PharmD, RPh; and Jason Peterson, RPh Weight management isn’t just a personal issue—it’s
Prescription for Trouble: Why Employers Must Act Now on Pharmacy Fiduciary Oversight
As cost-sharing increasingly shifts toward employees, employers are facing growing scrutiny over their pharmacy benefit strategies. Employees, frustrated by rising
2025 FDA Q1 Drug Approvals and Launches to Watch: Stelara Biosimilars, Non-Opioid Pain Relief & More
By Beckie Fenrick, PharmD, MBA; Emily Crisano, PharmD, RPh; and Jason Peterson, RPh The first quarter of 2025 has brought
